Journal article

Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer

MoonSun Jung, Amanda J Russell, Catherine Kennedy, Andrew J Gifford, Kylie-Ann Mallitt, Siva Sivarajasingam, David D Bowtell, Anna DeFazio, Michelle Haber, Murray D Norris, Michelle J Henderson



Background: The Myc oncogene family has been implicated in many human malignancies and is often associated with particularly aggressive disease, suggesting Myc as an attractive prognostic marker and therapeutic target. However, for epithelial ovarian cancer (EOC), there is little consensus on the incidence and clinical relevance of Myc aberrations. Here we comprehensively investigated alterations in gene copy number, expression, and activity for Myc and evaluated their clinical significance in EOC. Methods: To address inconsistencies in the literature regarding the definition of copy number variations, we developed a novel approach using quantitative polymerase chain reaction (qPCR) coupled ..

View full abstract


Awarded by Cancer Institute NSW

Awarded by NHMRC

Awarded by U.S. Army Medical Research and Materiel Command

Funding Acknowledgements

This project was supported by grants from the Cancer Institute New South Wales and the National Health and Medical Research Council (NHMRC) of Australia. Children's Cancer Institute Australia is affiliated with UNSW Australia and the Sydney Children's Hospitals Network. We acknowledge the contribution of the Australian Ovarian Cancer Study (AOCS; full list of the institutions that supported that study can be found at and the Gynecological Oncology Biobank at Westmead. The Westmead Gynaecological Oncology Biobank at Westmead was supported by the Cancer Institute NSW (12/RIG/1-17 and 15/RIG/1-16) and NHMRC (ID310670, ID628903). The Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the NHMRC (ID400413 and ID400281).